Lifeward

Lifeward

Lifeward Ltd., formerly known as ReWalk Robotics Ltd., is an Israeli-founded medical device company that develops, manufactures, and markets wearable robotic exoskeletons and rehabilitation systems. The company was originally established to commercialize technology invented by Dr. Amit Goffer, who founded the business after a quadriplegia-causing accident. The flagship product, the ReWalk Personal Exoskeleton, received FDA clearance in 2014 for use by individuals with spinal cord injuries, making it the first powered exoskeleton to achieve that regulatory milestone in the United States. A later version cleared for stroke rehabilitation expanded the addressable market. The company maintains its research and development footprint in Israel while conducting commercial operations primarily from the United States and Germany. Lifeward's strategy rests on securing broad payer coverage for its durable medical equipment. The ReWalk Personal Exoskeleton has a Healthcare Common Procedure Coding System code assigned by CMS, which allows direct Medicare billing. Coverage policy varies by Medicare Administrative Contractor region, and the Veterans Health Administration represents a major procurement channel. The company's second major product line, the AlterG anti-gravity treadmill, uses differential air pressure technology to reduce effective body weight during rehabilitation, serving a wider patient population including orthopedic, neurological, and sports medicine patients. Geographic revenue is concentrated in the United States and Germany, where statutory health insurance reimbursement pathways exist. In 2023 the company rebranded from ReWalk Robotics to Lifeward Ltd., consolidating the product portfolio under a unified commercial structure. Lifeward is publicly traded on the Nasdaq Capital Market under the ticker LFWD. The company has historically operated with a lean commercial team and a relatively concentrated institutional shareholder base. As of its most recent public filings, the company does not report a large-scale asset management operation; its balance sheet is funded through equity offerings and product revenue rather than managed third-party capital. A key operational event was the August 2023 completion of the merger between ReWalk Robotics Ltd. and AlterG Inc., which added the anti-gravity treadmill franchise and created the combined Lifeward entity. The company does not operate philanthropic foundations or co-investment vehicles; it functions as a pure-play medical technology operating company. What structurally differentiates Lifeward from broader MedTech peers is its singular exposure to CMS coverage policy as a binary catalyst. Rather than competing on patient volume alone, the firm's valuation and revenue trajectory hinge on geographic expansion of Medicare Administrative Contractor coverage decisions and the clinical evidence dossiers that support them. This makes it unusually dependent on health policy outcomes relative to a diversified device manufacturer, a dynamic not fully captured by standard sector classifications.